Lutz Wollin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4127809/publications.pdf

Version: 2024-02-01

	1040056	1474206
1,700	9	9
citations	h-index	g-index
9	9	2309
docs citations	times ranked	citing authors
		1,700 9 citations h-index

#	Article	IF	CITATIONS
1	Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. European Respiratory Journal, 2015, 45, 1434-1445.	6.7	667
2	Antifibrotic and Anti-inflammatory Activity of the Tyrosine Kinase Inhibitor Nintedanib in Experimental Models of Lung Fibrosis. Journal of Pharmacology and Experimental Therapeutics, 2014, 349, 209-220.	2.5	501
3	Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. Annals of the Rheumatic Diseases, 2016, 75, 883-890.	0.9	154
4	Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1941-1948.	0.9	149
5	Effects of nintedanib on the microvascular architecture in a lung fibrosis model. Angiogenesis, 2017, 20, 359-372.	7.2	107
6	Alteration of human macrophage phenotypes by the anti-fibrotic drug nintedanib. International Immunopharmacology, 2019, 72, 112-123.	3.8	38
7	TNF-α and IL-10 Control CXCL13 Expression in Human Macrophages. Journal of Immunology, 2020, 204, 2492-2502.	0.8	34
8	Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis–associated interstitial lung disease. Journal of Scleroderma and Related Disorders, 2019, 4, 212-218.	1.7	31
9	Effects of Nintedanib in an Animal Model of Liver Fibrosis. BioMed Research International, 2020, 2020, 1-9.	1.9	19